The historical rank and industry rank for PetVivo Holdings's Gross Margin % or its related term are showing as below:
PETV'
s Gross Margin % Range Over the Past 10 Years
Min: -400 Med: -29.38 Max: 51.43
Current: 51.43
During the past 13 years, the highestGross Margin % of PetVivo Holdings was 51.43%. The lowest was -400.00%. And the median was -29.38%.
PETV's Gross Margin % is ranked worse than 52.89% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 53.575
vs PETV: 51.43
PetVivo Holdings had a gross margin of 69.30% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for PetVivo Holdings was 0.00% per year.
PetVivo Holdings Gross Margin % Historical Data
The historical data trend for PetVivo Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PetVivo Holdings's Gross Margin %
For the Medical Devices subindustry, PetVivo Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetVivo Holdings's Gross Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where PetVivo Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PetVivo Holdings had a gross margin of 69.30% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
PetVivo Holdings Gross Margin % Related Terms
Thank you for viewing the detailed overview of PetVivo Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
PetVivo Holdings (PetVivo Holdings) Business Description
PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PETV has been successfully added to your 